RxDoctor Payments Data

Julian Esteban, MD

Interventional Cardiology · Lancaster, PANPI 1447228770

Payments from drug & device makers

$3,840in general payments, 2019–2025

Across 172 payments — averaging $22.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$702
  • Novartis$653
  • Amgen$401
  • Medtronic$367
  • Pfizer$187
  • Amarin Pharma, Inc.$181
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$3,840100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,840 in reported general payments places this provider in the 30th percentile of 281 interventional cardiology providers in Pennsylvania.

See all interventional cardiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$139,074
Medicare patients
434
Services billed
4,721

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban107$125,824
EntrestoSacubitril/Valsartan69$67,015
JardianceEmpagliflozin38$36,082
XareltoRivaroxaban21$19,416
Repatha SureclickEvolocumab20$16,191
Metoprolol Succinate216$2,993
Valsartan114$2,867
Ezetimibe101$2,505
Rosuvastatin Calcium131$2,252
Atorvastatin Calcium174$1,485
Flecainide Acetate16$1,363
ClopidogrelClopidogrel Bisulfate71$742
Amlodipine Besylate137$510
Doxazosin Mesylate16$490
Isosorbide Mononitrate ErIsosorbide Mononitrate21$477

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$187$125,824107 claims
NovartisEntresto$653$67,01569 claims
Boehringer IngelheimJardiance$164$36,08238 claims
Johnson & JohnsonXarelto$118$19,41621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 281 interventional cardiology providers in Pennsylvania.

Other interventional cardiology in Lancaster

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →